EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)

Hiroyuki Nagase, Konomi Kobayashi, Makiko Toma-Hirano, Maho Suzukawa, Norihiro Harada, Katsunori Masaki, Yoshito Miyata, Mayoko Tsuji, Junko Terada-Hirashima, Keiko Komatsuzaki, Hitoshi Sasano, Kenji Mizumura und 14 weitere

Allergology International · 2025

DOI: 10.1016/j.alit.2024.12.005 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Allergology International, 2025. Verfasst von Hiroyuki Nagase und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, …. Hauptthemen laut MEDLINE: Asthma, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline, GlaxoSmithKline KK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although randomized controlled trials (RCT) have demonstrated the efficacy of mepolizumab for asthma, they have excluded certain patient subgroups. To bridge the gap between RCT and real-world practice, the effectiveness of mepolizumab in a diverse population, including those potentially excluded from RCT, was assessed. Its effects on imaging findings and symptoms of chronic rhinosinusitis (CRS) with asthma were also assessed. METHODS: This retrospective observational study of patients in Japan (J-Real-Mepo: UMIN000045021) evaluated multiple endpoints and analyzed the relationship between clinical background and treatment outcomes. RESULTS: Mepolizumab significantly reduced exacerbations, improved Asthma Control Test (ACT) scores, and forced expiratory volume in 1 s, and reduced oral corticosteroid (OCS) dose, regardless of patient characteristics, including age, body mass index, smoking history, and comorbidities. Regarding RCT exclusion criteria, 29.4 % of patients had no history of exacerbations. Although 25.4 % of these patients required continuous OCS, the OCS dose was reduced similar to those with a history of exacerbations. Disease control and mepolizumab effectiveness in patients with a smoking history ≥10 pack-years was similar to that of never-smokers. Patients with eosinophil counts

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaSinusitisAntibodies, Monoclonal, HumanizedRhinitisAnti-Asthmatic AgentsHumansMaleFemaleMiddle AgedTreatment OutcomeJapanRetrospective StudiesAgedAdultRhinosinusitisEast Asian People

Stichwörter der Autor:innen

Eosinophilic asthmaEosinophilic chronic rhinosinusitisExclusion criteriaLund–Mackay scoreReal-world

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan. Electronic address: nagaseh@…
  • Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan; Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan.
  • Teikyo Allergy Center, Teikyo University Hospital, Tokyo, Japan; Department of Otolaryngology, Faculty of Medicine, Teikyo University, Tokyo, Japan.
  • Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Förderung

  • GlaxoSmithKline
  • GlaxoSmithKline KK

Zitieren

APA

Nagase, H., Kobayashi, K., Toma-Hirano, M., Suzukawa, M., Harada, N., Masaki, K., Miyata, Y., Tsuji, M., Terada-Hirashima, J., Komatsuzaki, K., Sasano, H., Mizumura, K., Kagoya, R., Shimizu, Y., Yoshihara, S., Kihara, N., Miyazaki, Y., Koya, T., Sugihara, N., …, & J-Real-Mepo Investigators (2025). Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo). Allergology International. https://doi.org/10.1016/j.alit.2024.12.005

Vancouver

Nagase H, Kobayashi K, Toma-Hirano M, Suzukawa M, Harada N, Masaki K, et al. Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo). Allergology International. 2025. doi:10.1016/j.alit.2024.12.005

BibTeX
@article{Nagase2025,
  author = {Nagase, Hiroyuki and Kobayashi, Konomi and Toma-Hirano, Makiko and Suzukawa, Maho and Harada, Norihiro and Masaki, Katsunori and Miyata, Yoshito and Tsuji, Mayoko and Terada-Hirashima, Junko and Komatsuzaki, Keiko and Sasano, Hitoshi and Mizumura, Kenji and Kagoya, Ryoji and Shimizu, Yuya and Yoshihara, Shintaro and Kihara, Norio and Miyazaki, Yasunari and Koya, Toshiyuki and Sugihara, Naruhiko and Ishikawa, Nobuhisa and Hojo, Masayuki and Tagaya, Etsuko and Tanaka, Akihiko and Fukunaga, Koichi and Gon, Yasuhiro and J-Real-Mepo Investigators, J-Real-Mepo Investigators},
  title = {Real-world effectiveness of mepolizumab in Japanese asthma patients with diverse backgrounds: Improvements in rhinosinusitis imaging (J-Real-Mepo)},
  journal = {Allergology International},
  year = {2025},
  doi = {10.1016/j.alit.2024.12.005}
}
Kostenlos starten →